DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: TYSABRI (natalizumab)
       *****************************************************
       #Post#: 1651--------------------------------------------------
       (Abst.) Benefit-risk perception of Tysabri in neurologists and l
       arge cohort of MS patients
       By: agate Date: April 23, 2017, 7:47 pm
       ---------------------------------------------------------
       This study seems to be saying that MS patients were more willing
       to take the PML risk of Tysabri than their neurologists.
       From PubMed, April 23, 2017:
       [quote]J Neurol Sci. 2017 May 15;376:181-190.
       Benefit-risk perception of natalizumab therapy in neurologists
       and a large cohort of multiple sclerosis patients
       Heesen C1, Kleiter I2, Meuth SG3, Krämer J3, Kasper J4, Köpke
       S5, Gaissmaier W6.
       Author information
       1
       Institut für Neuroimmunologie und Multiple Sklerose (INIMS),
       Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 2046
       Hamburg, Germany. Electronic address: heesen@uke.uni-hamburg.de.
       2
       Department of Neurology, St. Josef-Hospital,
       Ruhr-University-Bochum, Gudrunstr. 56, 44791 Bochum, Germany.
       3
       Department of Neurology, Neurology Clinic and Institute of
       Translational Neurology, Westfälische Wilhelms University,
       Albert Schweizer Campus 1, 48149 Münster, Germany.
       4
       Department of Health and Caring Sciences, Faculty of Health
       Sciences, University of Tromsø, Hansine Hansens veg 18, 9019
       Tromsø, Norway.
       5
       Institute of Social Medicine, University Hospital
       Schleswig-Holstein, Ratzeburger Allee 160, 23538 Lübeck,
       Germany.
       6
       Department of Psychology, University of Konstanz,
       Universitätsstraße 10, 78464 Konstanz, Germany.
       BACKGROUND:
       Natalizumab (NAT) is associated with the risk of progressive
       multifocal leukoencephalopathy (PML). Risk stratification
       algorithms have been developed, however, without detectable
       reduction of PML incidence.
       OBJECTIVE:
       To evaluate to which extent patients and physicians understand
       and accept risks associated with NAT treatment.
       METHODS:
       Prospective observational cohort study in German MS centers
       (n=73) among NAT-treated MS patients (n=801) and their
       neurologists (n=99). Patients included in this study had mean
       disease duration of 10.2years and a mean NAT treatment duration
       of 24months.
       RESULTS:
       More than 90% of patients and physicians voted for shared
       decision making or an informed choice decision making approach.
       Patients and physicians perceived a similar threat from MS as
       serious disease and both overestimated treatment benefits from
       NAT based on trial data. Men perceived MS more severe than women
       and perception of seriousness increased with age in both groups
       and in patients as well with increasing disability. Although
       patients evaluated their PML risk higher, their risk acceptance
       was significantly higher than of their neurologists. Risk
       stratification knowledge was good among neurologists and
       significantly lower among patients.
       CONCLUSION:
       While patients and physicians seem to have realistic risk
       perception of PML and knowledge of risk stratification concepts,
       the threat of MS and the perception of treatment benefits may
       explain the ongoing high acceptance of PML risk.[/quote]
  HTML https://www.ncbi.nlm.nih.gov/pubmed/28431609
  HTML https://www.ncbi.nlm.nih.gov/pubmed/28431609
       *****************************************************